New Directors

Anteris’ latest SEC filing [link here] details the addition of two new directors and the departure of another. Dr Wenyi Gu is a legacy appointment from the now spun-off vaccine development component of Admedus (as Anteris was formerly named). His expertise is in immunology and vaccines. His resignation was not unexpected and appears to be amicable.

Gregory Moss appears to be his immediate replacement. A lawyer admitted to jurisdictions of both Australia and the United States — he appears to be either another expat like Wayne Paterson, or an American with strong ties to Australia. His bio from his current employer (Evommune) indicates he has a background in compliance and some experience with acquisitions. He seems like a good choice for the company that Anteris is at the moment — with a footing on both sides of the Pacific and likely to need a good lawyer.

The second new director is David Roberts — President of NASDAQ company LeMaitre Vascular. It seems like another good choice, bringing experience and credibility from the American medtech space. LeMaitre currently holds the licence to sell Anteris’ ‘Cardiocel’ tissue repair product (part of the ADAPT platform). With a market cap of 1.9 billion USD they could make a sensible suitor for a partnership if Anteris’ capital situation becomes grim.